Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Integrum ABFRA:6Y1 -5.46%53 Debt-to-EBITDA is 0.18 as of Jul. 2026. GuruFocus rates FRA:6Y1 with a GF Score™ of 53/100 and a GF Value™ of €1.44 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 471 Medical Devices & Instruments companies, Integrum AB ranks worse than 212314.01% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Integrum AB's Debt-to-EBITDA or its related term are showing as below:
FRA:6Y1'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2 Med: -0.13 Max: 0.73
Current: -0.1
During the past 12 years, the highest Debt-to-EBITDA Ratio of Integrum AB was 0.73. The lowest was -2.00. And the median was -0.13.
FRA:6Y1's Debt-to-EBITDA is ranked worse than 100% of 471
companies
in the Medical Devices & Instruments industry
Industry Median: 1.63
vs FRA:6Y1: -0.10
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Integrum AB Debt-to-EBITDA Related Terms
Integrum AB Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Integrum AB's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6Y1 vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Integrum AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integrum AB Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Integrum AB's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Integrum AB's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jul. 2026) EBITDA data.
Integrum AB (FRA:6Y1) has a Debt-to-EBITDA of 0.18 as of Jul. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Integrum AB. According to the industry distribution chart, Integrum AB ranks #999999 out of 471 companies in the Medical Devices & Instruments industry.
Is Integrum AB's Debt-to-EBITDA too high?
Integrum AB's current Debt-to-EBITDA is 0.18. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.63. Integrum AB's value of 0.18 is 89% below this industry median. Based on the distribution chart, Integrum AB ranks #999999 out of 471 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Integrum AB has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Integrum AB's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Integrum AB ranks #999999 out of 471 companies for Debt-to-EBITDA. This places Integrum AB in the lower half of its industry. The industry median Debt-to-EBITDA is 1.63. Integrum AB's value of 0.18 is 89% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.63, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Integrum AB's current Debt-to-EBITDA of 0.18 is 89% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Integrum AB. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Integrum AB's current Debt-to-EBITDA is 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrum AB stock overvalued right now?
Based on GuruFocus' analysis, Integrum AB (FRA:6Y1) is currently considered Possible Value Trap. The stock's GF Value™ is €1.44, compared to a current price of €0.78 — trading 45.9% below its estimated fair value. The current Debt-to-EBITDA is 0.18 and 89% below the Medical Devices & Instruments industry median of 1.63. Integrum AB's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Integrum AB (FRA:6Y1), the current Debt-to-EBITDA is 0.18 as of Jul. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integrum AB (FRA:6Y1) Overvalued in 2026?
Based on GuruFocus' analysis, Integrum AB stock appears to be undervalued.
The current stock price of €0.78 is trading 45.9% below its estimated GF Value™ of €1.44.
GuruFocus considers Integrum AB to be Possible Value Trap.
Key valuation signals for FRA:6Y1:
Debt-to-EBITDA: 0.18
GF Value™: €1.44 vs. price of €0.78 (45.9% below fair value)
Industry Position: 89% below the Medical Devices & Instruments median (#999999 of 471)
No single metric tells the full story. See the FRA:6Y1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integrum AB provides the system for bone-anchored prostheses that improves the lives of people with amputations. Its solutions include OPRA implant system, Neural prosthetics, Phantom limb pain treatment, and Prosthetic components. The company is also engaged in developing technology for mind-controlled prostheses and treatment for phantom limb pain.
53GF Score
Get the complete analysis for FRA:6Y1
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6Y1 has been successfully added to your 
